Gilde Healthcare closes €145 million ($200 million) transatlantic growth capital fund - Gilde Healthcare

Gilde Healthcare closes €145 million ($200 million) transatlantic growth capital fund

November 26, 2013

Utrecht (The Netherlands) and Cambridge (USA, MA) – Gilde Healthcare, the specialist investment firm, today announces the final close of its €145 million ($200 million) transatlantic growth capital fund, Gilde Healthcare III (GHC III). The new fund targets investment in innovative businesses in home and digital health, medical devices, diagnostics and therapeutics both in the United States and in Europe.

GHC III closed at its original target, a major achievement in today’s fundraising environment. The fund is backed by a balanced mix of international corporate and institutional investors including (public) fund-of-funds, family offices, entrepreneurs and Gilde partners. Investors are attracted by Gilde Healthcare’s strong track record of value realization, the most recent of which include the $230 million trade sale of Dutch hemostasis company ProFibrix to The Medicines Company followed by the IPO of Conatus Pharma at Nasdaq. 

The fund has a differentiated investment strategy with a focus on companies that are delivering better healthcare solutions at lower cost. Gilde Healthcare’s hands-on investment team on both sides of the Atlantic actively supports the international growth of its companies. The fund will make equity investments of up to €15 million in a single portfolio company.

GHC III has already invested in four companies and more are expected to be closed before year end. The most recent investment is Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson's disease. Furthermore, the GHC III portfolio includes Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions, iWalk which commercializes bionic prosthetics for lower leg amputees and Definiens, the leading provider of image analysis software for digital pathology. In total GHC III plans to make up to twelve investments.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, MA, USA) is a transatlantic investment firm specialized in healthcare. It has over €450 million ($600 million) under management in four funds. Apart from three funds dedicated to technological innovations, Gilde Healthcare manages a separate fund aimed at mid-market healthcare service companies.

For a list of Gilde Healthcare’s portfolio companies please visit the website at www.gildehealthcare.com.

Contact
Pieter van der Meer
Managing Partner

Gilde Healthcare
Tel: +31.30.219.2528
www.gildehealthcare.com

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
October 5, 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
October 4, 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
September 29, 2021